The Latest Breaking News from AbbVie

Here are just a few of the many examples of drug pricing practices that have driven consumers to demand change

Revance's frown-line injection, Daxxify, gained U.S. approval on Monday to treat an involuntary movement disorder, and RVNC stock rose.

The pharma industry is poised to witness long-term growth with the introduction of generic medicines and growing demand for personalized and targeted treatments. Hence, fundamentally strong pharma stock AbbVie (ABBV) might be worth buying. However, it might not be the right time to invest in Pfizer (PFE). Keep reading.

AbbVie's underperformance, Jim Lebenthal sees Deere as a catch-up trade, and analysts await Pioneer's earnings report.

It’s the last day of the trading week, so investors are looking for extra spending money for the weekend ahead. Here are three unusually active put options to sell: high-paying and worthwhile long-term holds.

Drug maker AbbVie reported second-quarter profit and sales that fell from a year earlier but topped expectations. AbbVie stock rose.

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Patients who take the autoimmune disease treatment Humira may see some price relief when several lower-cost, biosimilar versions of the AbbVie drug reach the U.S. market in July

These 3 dividend stocks have uninterruptedly paid and raised their dividends for years. Further, these stocks have outperformed the broader markets, and Wall Street analysts have a favorable outlook on them.

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

The best retirement stocks ideally have attractive dividends that can be sustained. This can lead to steady income and long-term value for retirees.